First Command Advisory Services’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$66.9K Buy
1,395
+1,029
+281% +$44.2K ﹤0.01% 382
2026
Q1
$13.5K Hold
366
﹤0.01% 555
2025
Q4
$18.6K Buy
366
+36
+11% +$1.84K ﹤0.01% 422
2025
Q3
$18.3K Hold
330
﹤0.01% 394
2025
Q2
$22.8K Sell
330
-21
-6% -$1.43K ﹤0.01% 357
2025
Q1
$24.4K Buy
351
+327
+1,363% +$27K ﹤0.01% 332
2024
Q4
$2.06K Hold
24
﹤0.01% 415
2024
Q3
$2.86K Hold
24
﹤0.01% 411
2024
Q2
$3.43K Hold
24
﹤0.01% 415
2024
Q1
$3.08K Buy
+24
New +$2.86K ﹤0.01% 427

Other funds holding NVO

First Command Advisory Services's NVO Position: Q2 2026 in Review

First Command Advisory Services increased its Novo Nordisk (NVO) stake by 281% in Q2 2026, buying an estimated $44.2K and bringing the position to 1,395 shares worth $66.9K. The position accounts for ﹤0.01% of the portfolio, ranked #382.

First Command Advisory Services first reported a position in NVO in Q1 2024 and has held it in 10 quarters since. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • First Command Advisory Services held 1,395 shares of Novo Nordisk worth $66.9K as of Q2 2026.
  • First Command Advisory Services bought 1,029 Novo Nordisk shares in Q2 2026, an estimated $44.2K.
  • Novo Nordisk made up ﹤0.01% of First Command Advisory Services's portfolio in Q2 2026, its #382 holding.
  • First Command Advisory Services first reported a position in Novo Nordisk in Q1 2024 and has held it in 10 quarters since.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on First Command Advisory Services's 13F filing for Q2 2026, filed 10 Aug 2026.